Clozapine N-oxide, compound 21, and JHU37160 do not influence effortful reward-seeking behavior in mice.

ABSTRACT:

Rationale

Clozapine N-oxide (CNO) has been developed as a ligand to selectively activate designer receptors exclusively activated by designer drugs (DREADDs). However, previous studies have revealed that peripherally injected CNO is reverse-metabolized into clozapine, which, in addition to activating DREADDs, acts as an antagonist at various neurotransmitter receptors, suggesting potential off-target effects of CNO on animal physiology and behaviors. Recently, second-generation DREADD agonists compound 21 (C21) and JHU37160 (J60) have been developed, but their off-target effects are not fully understood.

Objectives

The present studies assessed the effect of novel DREADD ligands on reward-seeking behavior.

Methods

We first tested the possible effect of acute i.p. injec

SUBMITTER: Aomine Y 

PROVIDER: S-EPMC10774210 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature